The purpose of this study is to evaluate the effects of oral cannabidiol (CBD) compared to a placebo on smoking cessation. People aged 18-65 years who are current daily tobacco smokers with an interest in quitting may join.  The study will take place on the Johns Hopkins Bayview Medical Center campus at the Johns Hopkins Behavioral Pharmacology Research Unit. If you qualify and choose to take part in this study, compensation of up to $615 can be earned for completing all portions of the study procedures and following all study requirements.

Study Participation consists of:
21 experimental test sessions over the course of 6 weeks. The study will be completed in 3 phases, each lasting two weeks. Study weeks 1, 3, and 5 will be baseline weeks, during which you will smoke cigarettes as you normally would. Study weeks 2, 4, and 6 will be simulated quit attempt weeks, during which you will be asked to attempt to quit smoking cigarettes. You will be at the BPRU for up to 2 hours during each study visit, though most sessions will be about 30 minutes

All calls and participation related to this study are confidential: This survey will be collecting information about you. Your taking part in this survey is completely voluntary. Whether you join the study or not, the information collected today may be seen by researchers at Johns Hopkins, any sponsor of the study, and those responsible for oversight of the study. We try to make sure that the information we collect from you is kept private and used only for the research study we are discussing. The information we collect from you is kept confidential and used only for the research study we are discussing. If you do not agree to continue this survey, it will not affect your current or future care at Johns Hopkins. Your personal information will be kept if you choose not to enroll in the study or if you do not qualify to be in the study. We keep your information so that we do not call the same people twice, nor screen people multiple times for the same study